The Japanese encephalitis vaccine is one of the most important — yet most overlooked — travel vaccines for visitors to Asia and the Western Pacific. Japanese encephalitis (JE) is a mosquito-borne viral infection that causes inflammation of the brain, and while the overall risk to short-term urban travelers is low, the consequences of infection can be devastating.
Most JE infections are asymptomatic or cause mild flu-like illness. However, roughly 1 in 250 infections progresses to severe encephalitis, and among those who develop clinical disease, the case fatality rate is 20-30%. Up to 50% of survivors suffer permanent neurological damage. There is no antiviral treatment — only supportive care.
Japanese encephalitis by the numbers
Clinical JE cases per year globally
68,000
Case fatality rate in severe disease
20-30%
Endemic countries in Asia-Pacific
24
Ixiaro vaccine schedule
2 doses
What Is Japanese Encephalitis?
Japanese encephalitis is caused by the JE virus, a flavivirus closely related to dengue, Zika, and West Nile viruses. The virus is transmitted through the bite of infected Culex mosquitoes — primarily Culex tritaeniorhynchus — which breed in rice paddies, marshlands, and irrigated agricultural areas.
The transmission cycle involves mosquitoes, pigs (amplifying hosts), and wading birds (reservoir hosts). Humans are "dead-end" hosts — they do not develop high enough viremia to infect feeding mosquitoes. This is why JE transmission is concentrated in rural agricultural areas where rice cultivation and pig farming coexist.
Transmission pattern
JE mosquitoes (Culex species) are most active at dusk and dawn, unlike Aedes mosquitoes that transmit dengue during the day. Peak transmission occurs during the rainy season (monsoon months) when mosquito populations explode in flooded rice paddies.
Why is it called "Japanese" encephalitis?
The virus was first isolated in Japan in 1935, but JE is not primarily a Japanese disease today. Japan has largely eliminated domestic transmission through childhood vaccination and agricultural changes. The highest burden is now in India, Bangladesh, Nepal, Myanmar, and parts of Southeast Asia.
Where Is Japanese Encephalitis a Risk?
JE is endemic across much of Asia and the Western Pacific. The WHO estimates that 3 billion people live in JE-endemic regions. However, risk varies dramatically by country, season, and specific activities.
JE risk by destination
Highest Risk — vaccine strongly recommended
High transmission, limited domestic vaccination coverage
- India (especially Uttar Pradesh, Bihar, Assam, West Bengal)
- Bangladesh, Nepal, Myanmar
- Cambodia, Laos, Vietnam (rural areas)
- Indonesia (Bali rice terraces, Java, Sumatra)
Moderate Risk — vaccine recommended for rural/extended travel
Transmission occurs but domestic vaccination programs reduce risk
- Thailand (northern and central regions, rainy season)
- Philippines (Luzon, Mindanao rice-growing areas)
- China (southern and eastern provinces)
- Malaysia (Sarawak, Penang rural areas)
- Papua New Guinea, Torres Strait (Australia)
Low Risk — vaccine generally not needed for short urban trips
Effective childhood vaccination or limited transmission
- Japan (sporadic cases, excellent domestic vaccination)
- South Korea, Taiwan (low incidence)
- Singapore, Hong Kong, Brunei (urban, minimal rice agriculture)
- Australia (mainland — rare, Torres Strait only)
No Risk
JE does not occur
- Europe, Africa, Americas, Middle East
- Central and West Asia (west of Pakistan)
For Southeast Asia-specific guidance, see: Travel Vaccinations for Southeast Asia.
Who Should Get the Japanese Encephalitis Vaccine?
The CDC and WHO do not recommend the JE vaccine for all travelers to Asia. Instead, vaccination is based on a risk assessment considering destination, duration, season, and planned activities.
Vaccination recommended if any apply
- ○Spending 1 month or more in a JE-endemic area
- ○Traveling to rural or agricultural areas (rice paddies, farms)
- ○Staying in accommodations without air conditioning or screens
- ○Participating in extensive outdoor activities (hiking, cycling, camping)
- ○Visiting during the rainy/monsoon season (peak transmission)
- ○Working in agriculture, animal husbandry, or field research
- ○Traveling to areas with a known JE outbreak
- ○Frequent or recurrent travel to endemic areas
Short trips can still be high-risk
Even if your trip is shorter than 1 month, consider the vaccine if you plan extensive outdoor activities in rural areas during the rainy season. The combination of rural setting + monsoon + outdoor exposure significantly increases risk. A 2-week rice terrace trek in Bali during wet season carries more risk than a month in Bangkok.
Who does NOT typically need JE vaccine?
Short-term travelers (<1 month) visiting only urban areas, staying in air-conditioned hotels, with limited outdoor exposure during non-monsoon months. Business travelers to cities like Tokyo, Bangkok, Singapore, or Kuala Lumpur generally do not need JE vaccination.
Japanese Encephalitis Vaccine Options
Ixiaro (IC51) — Inactivated Vero Cell Vaccine
Ixiaro is the primary JE vaccine available in the United States, Europe, Canada, and Australia. It is manufactured by Valneva and uses the inactivated SA14-14-2 virus strain grown in Vero cells.
Ixiaro key facts
- ○Type: Inactivated (killed) virus — safe for immunocompromised individuals
- ○Doses: 2 doses, given 28 days apart (Day 0 and Day 28)
- ○Accelerated schedule: 2 doses 7 days apart (approved in the EU and US for adults 18-65)
- ○Booster: One booster dose at 12-24 months if ongoing risk
- ○Long-term protection: Studies show antibodies persist for at least 5-10 years after primary series + booster
- ○Approved age: 2 months and older (US), 2 months and older (EU)
- ○Administration: Intramuscular injection (deltoid muscle)
Accelerated Ixiaro schedule
The accelerated 7-day schedule produces adequate protective antibodies in approximately 98% of recipients by Day 28 — similar to the standard 28-day schedule. This is useful for travelers with less than a month before departure. Note: long-term protection data for the accelerated schedule are more limited.
SA 14-14-2 Live Attenuated Vaccine
The live attenuated SA 14-14-2 vaccine (marketed as CD.JEVAX and others) is the most widely used JE vaccine globally, with over 500 million doses administered in China and other Asian countries. A single dose provides high efficacy (~98%) and durable immunity.
However, this vaccine is NOT available in the United States, most of Europe, or Australia. It is primarily used in endemic countries for routine childhood immunization. Travelers cannot typically access this vaccine unless they are in an endemic country.
JENVAC (Inactivated, Vero Cell — India)
JENVAC is an inactivated JE vaccine manufactured by Bharat Biotech for use in India's national immunization program. Like Ixiaro, it is based on an inactivated virus strain. It is not widely available outside India.
When to Get the JE Vaccine Before Travel
Timing is critical with the JE vaccine because the standard schedule requires two doses given 28 days apart, with full protection developing approximately 1 week after the second dose.
Timing your JE vaccination
- ○Ideal: Start 6-8 weeks before departure (allows standard 28-day schedule + buffer)
- ○Minimum (standard): Start 5 weeks before departure (Day 0 + Day 28 + 7 days to develop immunity)
- ○Accelerated: Start 2 weeks before departure (Day 0 + Day 7 + 7 days to develop immunity)
- ○Too late: If departing in less than 2 weeks, the accelerated schedule may not provide full protection
For help planning your full vaccine schedule, see our Japan Travel Health Guide.
Side Effects of Ixiaro (JE Vaccine)
Ixiaro is generally well tolerated. The most common side effects are mild and resolve within a few days:
Common side effects
- ○Injection site pain, redness, or swelling (20-30%)
- ○Headache (15-25%)
- ○Muscle pain / myalgia (10-15%)
- ○Fatigue (10-15%)
- ○Low-grade fever (5-10%)
- ○Nausea (<5%)
Allergic reactions
Severe allergic reactions (anaphylaxis) are extremely rare but have been reported. The CDC recommends that travelers remain at the clinic for 30 minutes after each dose for observation. If you have had a severe allergic reaction to a previous dose of Ixiaro or to any vaccine component (including protamine sulfate), do not receive this vaccine.
Historically, the older mouse-brain-derived JE vaccines (JE-VAX) were associated with a higher rate of allergic reactions (urticaria, angioedema). Ixiaro has a significantly better safety profile and replaced JE-VAX in most Western countries by 2011.
Beyond the Vaccine: Mosquito Bite Prevention
Even with vaccination, mosquito bite prevention remains important — both to reduce residual JE risk and to protect against other mosquito-borne diseases (dengue, malaria, Zika) for which no travel vaccine may be available.
Mosquito bite prevention checklist
- ○Use DEET (20-50%), picaridin, or IR3535-based insect repellent on exposed skin
- ○Wear long sleeves and pants during dusk and dawn (peak Culex activity)
- ○Sleep under a permethrin-treated bed net, especially in rural areas without screens
- ○Choose accommodations with air conditioning or screened windows
- ○Avoid outdoor activities near rice paddies or standing water at dusk
- ○Consider permethrin-treated clothing for extended rural travel
Frequently Asked Questions
Do I need the JE vaccine for Japan?
For most travelers, no. Japan has near-zero locally acquired JE cases due to high childhood vaccination coverage and changes in agriculture. The CDC does not routinely recommend JE vaccine for travelers to Japan unless they plan extended stays in rural areas during summer months. If you're visiting Tokyo, Kyoto, Osaka, or other cities, JE vaccine is generally unnecessary.
Do I need the JE vaccine for Bali?
Possibly. Bali has rice paddies and pig farming — two key risk factors for JE transmission. If you plan to visit rural Bali (Ubud rice terraces, Jatiluwih, Tabanan) during the wet season (October-April), the vaccine is worth considering, especially for stays longer than 2 weeks. Beach resort stays in Seminyak, Kuta, or Nusa Dua carry minimal risk.
Can I get the JE vaccine at the same time as other travel vaccines?
Yes. Ixiaro can be administered simultaneously with other vaccines, including hepatitis A, hepatitis B, typhoid, rabies, and yellow fever. Use separate injection sites. Co-administration does not reduce the effectiveness of any vaccine.
How much does the JE vaccine cost?
Ixiaro is one of the more expensive travel vaccines, typically costing $300-$400 USD per dose ($600-$800 for the full 2-dose series) in the United States. In Europe, it ranges from 60-100 EUR per dose. Some travel insurance plans and military/government programs cover JE vaccination. Check with your travel clinic about pricing.
Is the JE vaccine required for entry to any country?
No country currently requires proof of JE vaccination for entry. It is purely a recommendation based on risk. This differs from yellow fever, which is legally required for entry to certain countries.
Can children receive the JE vaccine?
Yes. Ixiaro is approved for children aged 2 months and older in the US and EU. The dose is 0.25 mL for children under 3 years and 0.5 mL for those 3 years and older. The same 2-dose schedule applies.
Related Reading
- Travel Vaccinations for Southeast Asia
- Japan Travel Health: Vaccines & Tips
- Mosquito-Borne Diseases: Prevention Guide
- Travel Vaccine Schedule: When to Start
- Japanese Encephalitis — Disease Overview
Important Disclaimer
Medical disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Japanese encephalitis vaccine recommendations depend on your specific itinerary, duration of travel, planned activities, season, and medical history. Always consult a travel medicine specialist for personalized advice before traveling to endemic areas.
Sources: WHO Position Paper on Japanese Encephalitis Vaccines (2015, updated 2024), CDC Yellow Book 2026, SAGE JE Review 2024. Last updated: April 2026.